Published in Nat Biotechnol on January 09, 2012
Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet (2014) 2.12
Moving stem cells to the clinic: potential and limitations for brain repair. Neuron (2015) 0.94
Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl Med (2015) 0.92
Clinical translation of autologous Schwann cell transplantation for the treatment of spinal cord injury. Curr Opin Organ Transplant (2013) 0.88
Biological characteristics of human-urine-derived stem cells: potential for cell-based therapy in neurology. Tissue Eng Part A (2014) 0.87
Managing the potential and pitfalls during clinical translation of emerging stem cell therapies. Clin Transl Med (2014) 0.81
BioTime acquires Geron's stem cell program. Nat Biotechnol (2013) 0.79
Using human induced pluripotent stem cells to model cerebellar disease: Hope and hype. J Neurogenet (2015) 0.78
Allogeneic Neural Stem/Progenitor Cells Derived From Embryonic Stem Cells Promote Functional Recovery After Transplantation Into Injured Spinal Cord of Nonhuman Primates. Stem Cells Transl Med (2015) 0.76
Commercialization and stem cell research: a review of emerging issues. Stem Cells Dev (2013) 0.76
Does the preclinical evidence for functional remyelination following myelinating cell engraftment into the injured spinal cord support progression to clinical trials? Exp Neurol (2016) 0.76
Cellular therapies for treating pain associated with spinal cord injury. J Transl Med (2012) 0.76
Magnetic nanoparticles for oligodendrocyte precursor cell transplantation therapies: progress and challenges. Mol Cell Ther (2014) 0.76
Cell Based Therapies: At Crossroads to find the right Cell source. J Stem Cells Regen Med (2012) 0.75
The Application of Human iPSCs in Neurological Diseases: From Bench to Bedside. Stem Cells Int (2016) 0.75
Coalition aims to accelerate translation of cell therapies. Nat Biotechnol (2012) 0.75
Geron trial resumes, but standards for stem cell trials remain elusive. Nat Biotechnol (2010) 2.81
An array of problems. Nat Rev Drug Discov (2005) 2.55
Drug discovery: playing dirty. Nature (2005) 2.12
2004 approvals: the demise of the blockbuster? Nat Rev Drug Discov (2005) 1.58
Set back to Alzheimer vaccine studies. Nat Med (2002) 1.43
Engineered T-cell therapy shows efficacy in blood cancer. Nat Biotechnol (2011) 1.17
Bortezomib. Nat Rev Drug Discov (2003) 1.09
The trouble with making combination drugs. Nat Rev Drug Discov (2006) 0.99
FDA publishes analysis of the pipeline problem. Nat Rev Drug Discov (2004) 0.93
How to avoid another 'Vioxx'. Nat Rev Drug Discov (2005) 0.91
Kidney specificity of rat chromosome 1 blood pressure quantitative trait locus region. Hypertension (2002) 0.86
Pipeline problems are increasing the urge to merge. Nat Rev Drug Discov (2006) 0.86
2003 approvals: a year of innovation and upward trends. Nat Rev Drug Discov (2004) 0.84
Pharma companies becoming more aggressive towards generics firms. Nat Rev Drug Discov (2006) 0.83
Drug approval triggers debate on future direction for cancer treatments. Nat Rev Drug Discov (2006) 0.83
Safety concerns raised over RNA interference. Nat Rev Drug Discov (2006) 0.82
How academia can help drug discovery. Nat Rev Drug Discov (2004) 0.82
Pharma faces major challenges after a year of failures and heated battles. Nat Rev Drug Discov (2007) 0.80
New drug approvals for 2002. Nat Rev Drug Discov (2003) 0.80
Pharma's year of trouble and strife. Nat Rev Drug Discov (2006) 0.80
Therapeutic area influences drug development costs. Nat Rev Drug Discov (2004) 0.79
Cancer drugs could now discover X factor. Nat Rev Drug Discov (2005) 0.79
Industry sweats after patent verdict. Nat Rev Drug Discov (2006) 0.77
Lessons learnt from Genasense's failure. Nat Rev Drug Discov (2004) 0.77
Vioxx risk could signify trouble in class. Nat Rev Drug Discov (2004) 0.76
Chemistry outsourcing going global. Nat Rev Drug Discov (2006) 0.75
Better antibiotics through chemistry. Nat Rev Drug Discov (2004) 0.75
Iressa failure raises fears about accelerated approvals. Nat Rev Drug Discov (2005) 0.75
Scientists slam rationale behind largest HIV vaccine trial. Nat Rev Drug Discov (2004) 0.75
New bill aims to reform US patent system. Nat Rev Drug Discov (2006) 0.75
Aventis-Sanofi: a good R&D merger? Nat Rev Drug Discov (2004) 0.75
New neglected disease research scheme pools IP and expertise. Nat Rev Drug Discov (2012) 0.75
Antidepressant use in children questioned. Nat Rev Drug Discov (2003) 0.75
Europe fiddles while innovation burns. Nat Rev Drug Discov (2005) 0.75
Calls for full disclosure of clinical trials. Nat Rev Drug Discov (2004) 0.75
Another long leaderless period in store for FDA. Nat Rev Drug Discov (2004) 0.75
Fine print TRIPS up multinational and Indian companies. Nat Rev Drug Discov (2005) 0.75
The biotechnology sector's craving for commercial expertise is fuelling a cultural exchange with drug industry. Nature (2003) 0.75
Vioxx fears prompt call for user fee evaluation. Nat Rev Drug Discov (2005) 0.75
PPPs succeeding in tackling neglected diseases. Nat Rev Drug Discov (2005) 0.75
Caution remains over stem cells despite breakthrough. Nat Rev Drug Discov (2005) 0.75
Study reveals secrets to faster drug development. Nat Rev Drug Discov (2006) 0.75
Heartbeat clue to diagnosing vCJD. Nat Med (2002) 0.75
Groups question existence of metabolic syndrome. Nat Rev Drug Discov (2005) 0.75
Big companies helped by safe harbour ruling. Nat Rev Drug Discov (2005) 0.75
Vaccine approach for Alzheimer's disease revisited. Nat Rev Drug Discov (2004) 0.75
Study shows newer schizophrenia treatments no more effective than old. Nat Rev Drug Discov (2005) 0.75
Drug safety special: chasing shadows. Nature (2005) 0.75